Clinical

Clinical

Sickle Cell Disease, SCD, (NCT04774536)
Sponsors:
Principal Investigator: Mark Walters, MD UCSF Benioff Children's Hospital Oakland
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
Relapsed/Refractory Haematopoietic Malignancies (NCT04767308)
Sponsors:
Huazhong University of Science and Technology
Indicator
IND Enabling
Phase I
Phase II
Phase III
T-Cell Chronic Lymphoblastic Leukaemia, CLL, (NCT04264078)
Sponsors:
Xinqiao Hospital of Chongqing
Indicator
IND Enabling
Phase I
Phase II
Phase III
Relapsed or Refractory B-cell Malignancies, (NCT03229876)
Sponsors:
Bioray Laboratories - Shanghai Bangyao Biotechnology Co., Ltd.
IND Enabling
Phase I
Phase II
Phase III
Beta-thalassemia, BT, (NCT04211480)
Sponsors:
Bioray Laboratories - Bangyao Biotechnology Co., Ltd. 
IND Enabling
Phase I
Phase II
Phase III
Beta - thalassemia, BT, (NCT04205435)
Sponsors:
Bioray Laboratories - Bangyao Biotechnology Co., Ltd. 
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
Relapsed or Refractory B-cell Malignancies, Non-Hodgkin lymphoma, NHL, (NCT04213469)
Sponsors:
Bioray Laboratories - Bangyao Biotechnology Co., Ltd. 
IND Enabling
Phase I
Phase II
Phase III
Indicator
IND Enabling
Phase I
Phase II
Phase III
close
Search CRISPR Medicine